Home/Global Research Enterprise Services/IP Management
|
|
The University for Sustainability facilitates licensing agreements enabling the uptake of member's cutting-edge research and technology into sustainable new products, processes and services. With an IP Portfolio that will soon include hundreds of patents for developed technologies, discover how businesses can access high-value risk-mitigated technologies available from the University's ecosystem. There are various ways to access the latest technologies from University's ecosystem.
Sample solutions:
Potential treatment for allergic disease including severe steroid resistant asthma
A novel approach shows promising results as a potential therapeutic for allergic conditions, including severe steroid resistant asthma. A peptide has been identified, HpARI, that inactivates and inhibits release of IL-33 a critical step in the development of allergic disease.
TECHNOLOGY
Our technology, HpARI, centres around a peptide derived from the secretions of a helminth parasite, and which we have shown blocks the release of IL-33 from cells, and binds to active IL-33 only. This dual strategy is a potentially more efficacious and efficient approach to treatment than current candidates.
HpARI suppresses allergic immune responses, lung pathology, and improves lung function through interference in the IL-33 pathway in in vivo and in vitro models. We have characterised the domains and binding sites necessary for activity, and the design of drugable peptides is currently underway
BENEFITS
TECHNOLOGY
Our technology, HpARI, centres around a peptide derived from the secretions of a helminth parasite, and which we have shown blocks the release of IL-33 from cells, and binds to active IL-33 only. This dual strategy is a potentially more efficacious and efficient approach to treatment than current candidates.
HpARI suppresses allergic immune responses, lung pathology, and improves lung function through interference in the IL-33 pathway in in vivo and in vitro models. We have characterised the domains and binding sites necessary for activity, and the design of drugable peptides is currently underway
BENEFITS
- A previously unknown mechanism to modulate IL-33
- More efficient approach than binding active and inactive form of IL-33; lower concentration required for effect
- Dual strategy differs from other anti-IL33 candidates
- Current tools are ineffective in detection and blockade of active IL-33
Bacterial strains for antibiotic drug discovery
This technology consists of 12 K. pneumoniae strains that which have been genetically engineered to carry mutations affecting key cell functions known to be implicated in the development of drug resistance including antimicrobial efflux, virulence, transcription factor regulation and membrane stability. These are useful set of strains for use in antibiotic drug discovery and screening.
HUMAN GLIOMA-DERIVED NEURONAL STEM CELL LINES AS A MODEL FOR DRUG SCREENING
These adherent glioma neural stem (GNS) cell lines retain the characteristics of the original tumour-initiating cells, delivering a powerful model system for chemical and genetic screening
